149 related articles for article (PubMed ID: 26281700)
1. [Current status and future prospects of research on Fukuyama muscular dystrophy].
Toda T
Nihon Rinsho; 2015 Aug; 73(8):1425-36. PubMed ID: 26281700
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy.
Taniguchi-Ikeda M; Kobayashi K; Kanagawa M; Yu CC; Mori K; Oda T; Kuga A; Kurahashi H; Akman HO; DiMauro S; Kaji R; Yokota T; Takeda S; Toda T
Nature; 2011 Oct; 478(7367):127-31. PubMed ID: 21979053
[TBL] [Abstract][Full Text] [Related]
3. Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression.
Ohtsuka Y; Kanagawa M; Yu CC; Ito C; Chiyo T; Kobayashi K; Okada T; Takeda S; Toda T
Sci Rep; 2015 Feb; 5():8316. PubMed ID: 25661440
[TBL] [Abstract][Full Text] [Related]
4. Antisense oligonucleotide induced pseudoexon skipping and restoration of functional protein for Fukuyama muscular dystrophy caused by a deep-intronic variant.
Enkhjargal S; Sugahara K; Khaledian B; Nagasaka M; Inagaki H; Kurahashi H; Koshimizu H; Toda T; Taniguchi-Ikeda M
Hum Mol Genet; 2023 Apr; 32(8):1301-1312. PubMed ID: 36426838
[TBL] [Abstract][Full Text] [Related]
5. Contribution of dysferlin deficiency to skeletal muscle pathology in asymptomatic and severe dystroglycanopathy models: generation of a new model for Fukuyama congenital muscular dystrophy.
Kanagawa M; Lu Z; Ito C; Matsuda C; Miyake K; Toda T
PLoS One; 2014; 9(9):e106721. PubMed ID: 25198651
[TBL] [Abstract][Full Text] [Related]
6. Mislocalization of fukutin protein by disease-causing missense mutations can be rescued with treatments directed at folding amelioration.
Tachikawa M; Kanagawa M; Yu CC; Kobayashi K; Toda T
J Biol Chem; 2012 Mar; 287(11):8398-406. PubMed ID: 22275357
[TBL] [Abstract][Full Text] [Related]
7. Deep-intronic variant of fukutin is the most prevalent point mutation of Fukuyama congenital muscular dystrophy in Japan.
Kobayashi K; Kato R; Kondo-Iida E; Taniguchi-Ikeda M; Osawa M; Saito K; Toda T
J Hum Genet; 2017 Nov; 62(11):945-948. PubMed ID: 28680109
[TBL] [Abstract][Full Text] [Related]
8. [Alpha-dystroglycanopathy (FCMD, MEB, etc): abnormal glycosylation and muscular dystrophy].
Toda T
Rinsho Shinkeigaku; 2005 Nov; 45(11):932-4. PubMed ID: 16447766
[TBL] [Abstract][Full Text] [Related]
9. Molecular interaction between fukutin and POMGnT1 in the glycosylation pathway of alpha-dystroglycan.
Xiong H; Kobayashi K; Tachikawa M; Manya H; Takeda S; Chiyonobu T; Fujikake N; Wang F; Nishimoto A; Morris GE; Nagai Y; Kanagawa M; Endo T; Toda T
Biochem Biophys Res Commun; 2006 Dec; 350(4):935-41. PubMed ID: 17034757
[TBL] [Abstract][Full Text] [Related]
10. Fukutin expression in mouse non-muscle somatic organs: its relationship to the hypoglycosylation of alpha-dystroglycan in Fukuyama-type congenital muscular dystrophy.
Saito Y; Yamamoto T; Ohtsuka-Tsurumi E; Oka A; Mizuguchi M; Itoh M; Voit T; Kato Y; Kobayashi M; Saito K; Osawa M
Brain Dev; 2004 Oct; 26(7):469-79. PubMed ID: 15351084
[TBL] [Abstract][Full Text] [Related]
11. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
[TBL] [Abstract][Full Text] [Related]
12. Fukuyama-type congenital muscular dystrophy (FCMD) and alpha-dystroglycanopathy.
Toda T; Kobayashi K; Takeda S; Sasaki J; Kurahashi H; Kano H; Tachikawa M; Wang F; Nagai Y; Taniguchi K; Taniguchi M; Sunada Y; Terashima T; Endo T; Matsumura K
Congenit Anom (Kyoto); 2003 Jun; 43(2):97-104. PubMed ID: 12893968
[TBL] [Abstract][Full Text] [Related]
13. National registry of patients with Fukuyama congenital muscular dystrophy in Japan.
Ishigaki K; Ihara C; Nakamura H; Mori-Yoshimura M; Maruo K; Taniguchi-Ikeda M; Kimura E; Murakami T; Sato T; Toda T; Kaiya H; Osawa M
Neuromuscul Disord; 2018 Oct; 28(10):885-893. PubMed ID: 30220444
[TBL] [Abstract][Full Text] [Related]
14. [Recent Advances in α-dystroglycanopathy].
Kuga A; Kanagawa M; Toda T
Brain Nerve; 2011 Nov; 63(11):1189-95. PubMed ID: 22068471
[TBL] [Abstract][Full Text] [Related]
15. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Touznik A; Lee JJ; Yokota T
Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
[TBL] [Abstract][Full Text] [Related]
16. [Pathomechanism and therapeutic strategy of Fukuyama congenital muscular dystrophy and related disorders].
Toda T
Rinsho Shinkeigaku; 2009 Nov; 49(11):859-62. PubMed ID: 20030231
[TBL] [Abstract][Full Text] [Related]
17. [Hint and luck for identification of a gene for Fukuyama muscular dystrophy, fukutin].
Toda T
Rinsho Shinkeigaku; 2007 Nov; 47(11):743-8. PubMed ID: 18210789
[TBL] [Abstract][Full Text] [Related]
18. Fukutin and alpha-dystroglycanopathies.
Toda T; Chiyonobu T; Xiong H; Tachikawa M; Kobayashi K; Manya H; Takeda S; Taniguchi M; Kurahashi H; Endo T
Acta Myol; 2005 Oct; 24(2):60-3. PubMed ID: 16550916
[TBL] [Abstract][Full Text] [Related]
19. Post-transcriptional regulation of fukutin in an astrocytoma cell line.
Yamamoto T; Kato Y; Hiroi A; Shibata N; Osawa M; Kobayashi M
Int J Exp Pathol; 2012 Feb; 93(1):46-55. PubMed ID: 22264285
[TBL] [Abstract][Full Text] [Related]
20. Novel mutation in the fukutin gene in an Egyptian family with Fukuyama congenital muscular dystrophy and microcephaly.
Ismail S; Schaffer AE; Rosti RO; Gleeson JG; Zaki MS
Gene; 2014 Apr; 539(2):279-82. PubMed ID: 24530477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
